Pharmaceutical
Learn about the latest developments in the pharmaceutical cannabis industry with Business of Cannabis. Discover new drugs, research, and more.
Pharmaceutical · page 10
- Pharmaceutical
GW Pharma begins constructing £75m UK cannabis manufacturing facility
GW Pharmaceuticals’ facility will create more than “100 highly skilled jobs”.
- Pharmaceutical
Jazz Pharmaceuticals Announces Significant New Investment in UK Manufacturing
JAZZ Pharmaceuticals plc (Nasdaq: JAZZ) and its subsidiary, GW Pharmaceuticals (“GW”) – a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines – today announced the official initiation of construction of its new, state-of-the-art manufacturing facility at Kent Science Park (KSP) in Sittingbourne.
- Pharmaceutical
How cannabis banking reform could happen this year
STAY SAFE Cantor Fitzgerald weighs in on SAFE Banking The only way for SAFE Banking to pass is if Senate Majority Leader Chuck Schumer allows it to be heard, go through committee and voted on, according to a memo by Cantor Fitzgerald and shared in a tweet by Insider’s Jeremy Berke.
- CBD Market
Review to establish greater strategic coherence for UK legal cannabis
The Hodges Review has been launched to review regulation and public policy relating to the UK’s industry.
- Pharmaceutical
OCT Co-Founder Publishes Scathing Letter Accusing Directors of ‘Serious Governance & Management’ Failings Ahead of GM Vote to Oust Board
GAVIN Sathianathan, a founder member of Oxford Cannabinoid Technologies (OCT), published a bombshell letter to fellow investors last week laying bare the numerous reasons behind his call for the company’s board to be replaced.
- Pharmaceutical
Construction of Tikun’s medical cannabis greenhouse complete
The facility has been completed ahead of schedule.
- Hemp Industry
New Jersey’s cannabis market on the cusp
GARDEN STATE INDEED New Jersey’s adult-use market could exceed $2 billion by 2025 With adult-use sales scheduled to launch within weeks, MJBizDaily took a deep dive into the state to project sales from 2022 to 2026.
- Pharmaceutical
EU Cannabis Stocks Review: OCT Board Accused of Serious Governance Issues by Co-Founder, Panaxia’s Debt Pile Hits Stock & More from Love Hemp
AS European Cannabis stocks continue their battle against external market forces, it has been internal battles which made the headlines this week.
- Pharmaceutical
Major shareholder appeals for urgent change at Oxford Cannabinoid Technologies
The appeal states there is an urgent need to address serious governance and sclerotic management issues.
- Pharmaceutical
Positive results for cannabinoid targeting multi-billion pain market
Oxford Cannabinoid Technologies has stated it will begin Phase I clinical trials early next year.
- Pharmaceutical
One Year After The First Cannabis Stocks Joined The LSE, Could We See A Fresh Run Of Cannabis IPOs This Year?
FEBRUARY 2022 marked the one-year anniversary of MGC Pharmaceuticals IPO on the London Stock Exchange, which saw cannabis stocks traded on the platform for the first time in its 320-year history.
- Pharmaceutical
Oxford Cannabinoid Technologies Says Data From Pre-Clinical Study of Leading Drug Candidate Shows Positive Results
OXFORD Cannabinoid Technologies Holdings plc (LSE: OCTP, OTCQB: OCTHF), the pharmaceutical company developing prescription cannabinoid medicines targeting the US$ multi-billion pain market is pleased to announce positive results from a pre-clinical pain study for its lead compound, OCT461201, targeting the global Chemotherapy Induced Peripheral Neuropathy (“CIPN”) treatment market valued at US$1.61bn in 2020 and forecasted…
